Merck's withdrawal of its 2013 EPS guidance and the setback with vorapaxar raise concerns about its near-term outlook. Despite strong Q4 results and growth in key markets, investor uncertainty regarding future earnings and pipeline challenges may lead to negative sentiment. Therefore, the stock is likely to face short-term pressure.

[-1]